Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents

W. J. Louis, J. J. McNeil, S. N. Anavekar, E. L. Conway, B. Workman, L. G. Howes, O. H. Drummer, B. Jarrott

Research output: Contribution to journalReview ArticleResearchpeer-review

10 Citations (Scopus)

Abstract

Central and peripheral α-adrenoceptors play an important role in cardiovascular regulation, and selective α1-adrenoceptor antagonists and α2-adrenoceptor agonists have an established place in the therapy of hypertension. Prazosin is a selective α1-antagonist that is both effective in lowering blood pressure and well tolerated. However, the more recently developed α1-antagonists doxazosin and terazosin offer the advantage of having longer half-lives, allowing once daily administration. Clonidine is a centrally acting α2-agonist whose clinical use has often been limited by the dose dependent side effects of dry mouth and sedation, and the belief that it should be given three times per day. However, recent studies have shown that it has substantial antihypertensive efficacy with minimal side effects at low doses, and that half-life is long enough to allow twice daily administration. An improved understanding of the pharmacodynamics and pharmacokinetics of drugs acting on α-adrenoceptors allows a more rational approach to their clinical application.

Original languageEnglish
JournalJournal of Cardiovascular Pharmacology
Volume10
Issue numberSUPPL. 12
Publication statusPublished - 1 Dec 1987

Cite this

@article{eb87d9bc5e394068ad13e2a3fa37ef84,
title = "Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents",
abstract = "Central and peripheral α-adrenoceptors play an important role in cardiovascular regulation, and selective α1-adrenoceptor antagonists and α2-adrenoceptor agonists have an established place in the therapy of hypertension. Prazosin is a selective α1-antagonist that is both effective in lowering blood pressure and well tolerated. However, the more recently developed α1-antagonists doxazosin and terazosin offer the advantage of having longer half-lives, allowing once daily administration. Clonidine is a centrally acting α2-agonist whose clinical use has often been limited by the dose dependent side effects of dry mouth and sedation, and the belief that it should be given three times per day. However, recent studies have shown that it has substantial antihypertensive efficacy with minimal side effects at low doses, and that half-life is long enough to allow twice daily administration. An improved understanding of the pharmacodynamics and pharmacokinetics of drugs acting on α-adrenoceptors allows a more rational approach to their clinical application.",
author = "Louis, {W. J.} and McNeil, {J. J.} and Anavekar, {S. N.} and Conway, {E. L.} and B. Workman and Howes, {L. G.} and Drummer, {O. H.} and B. Jarrott",
year = "1987",
month = "12",
day = "1",
language = "English",
volume = "10",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams & Wilkins",
number = "SUPPL. 12",

}

Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents. / Louis, W. J.; McNeil, J. J.; Anavekar, S. N.; Conway, E. L.; Workman, B.; Howes, L. G.; Drummer, O. H.; Jarrott, B.

In: Journal of Cardiovascular Pharmacology, Vol. 10, No. SUPPL. 12, 01.12.1987.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents

AU - Louis, W. J.

AU - McNeil, J. J.

AU - Anavekar, S. N.

AU - Conway, E. L.

AU - Workman, B.

AU - Howes, L. G.

AU - Drummer, O. H.

AU - Jarrott, B.

PY - 1987/12/1

Y1 - 1987/12/1

N2 - Central and peripheral α-adrenoceptors play an important role in cardiovascular regulation, and selective α1-adrenoceptor antagonists and α2-adrenoceptor agonists have an established place in the therapy of hypertension. Prazosin is a selective α1-antagonist that is both effective in lowering blood pressure and well tolerated. However, the more recently developed α1-antagonists doxazosin and terazosin offer the advantage of having longer half-lives, allowing once daily administration. Clonidine is a centrally acting α2-agonist whose clinical use has often been limited by the dose dependent side effects of dry mouth and sedation, and the belief that it should be given three times per day. However, recent studies have shown that it has substantial antihypertensive efficacy with minimal side effects at low doses, and that half-life is long enough to allow twice daily administration. An improved understanding of the pharmacodynamics and pharmacokinetics of drugs acting on α-adrenoceptors allows a more rational approach to their clinical application.

AB - Central and peripheral α-adrenoceptors play an important role in cardiovascular regulation, and selective α1-adrenoceptor antagonists and α2-adrenoceptor agonists have an established place in the therapy of hypertension. Prazosin is a selective α1-antagonist that is both effective in lowering blood pressure and well tolerated. However, the more recently developed α1-antagonists doxazosin and terazosin offer the advantage of having longer half-lives, allowing once daily administration. Clonidine is a centrally acting α2-agonist whose clinical use has often been limited by the dose dependent side effects of dry mouth and sedation, and the belief that it should be given three times per day. However, recent studies have shown that it has substantial antihypertensive efficacy with minimal side effects at low doses, and that half-life is long enough to allow twice daily administration. An improved understanding of the pharmacodynamics and pharmacokinetics of drugs acting on α-adrenoceptors allows a more rational approach to their clinical application.

UR - http://www.scopus.com/inward/record.url?scp=0023634367&partnerID=8YFLogxK

M3 - Review Article

VL - 10

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - SUPPL. 12

ER -